# A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)

Source: https://onco.cc/trials/nct07648914/  
OnCo record `nct07648914` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Capecitabine in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) is a phase 3 interventional study registered as NCT07648914 by Sichuan Baili Pharmaceutical Co., Ltd., with 446 participants planned, started 2026-07-06 and due to reach its primary completion in 2028-12. Interventions recorded: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel and Capecitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07648914
- Phase: 3
- Setting: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 446

## Sources

- ClinicalTrials.gov NCT07648914: https://clinicaltrials.gov/study/NCT07648914

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct07648914.json